As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Semnur Pharmaceuticals, Inc. The largest reported stake is Scilex Holding Company's, at 79.89%. One filing is on record since September 26, 2025 (Schedule 13D, September 26, 2025).
Sell to companies like Semnur Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Scilex Holding Company · Sole voting: 500,000 · Shared voting: 188,054,849 · Sole dispositive: 500,000 · Shared dispositive: 188,054,849 · SCHEDULE 13D, 2025-09-26
- · Reporting person: Scilex, Inc. · Sole voting: 0 · Shared voting: 181,804,849 · Sole dispositive: 0 · Shared dispositive: 181,804,849 · SCHEDULE 13D, 2025-09-26
- · Holder: Scilex Holding Company · Percent: 79.89% · SCHEDULE 13D
- · Holder: Scilex Holding Company · Percent: 79.89% · Shares: 188,554,849 · SCHEDULE 13D
Semnur Pharmaceuticals, Inc. has 1 Schedule 13D or 13G filing on record since 2025-09-26. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Scilex Holding Company | 79.89% | 188,554,849 | SCHEDULE 13D, 2025-09-26 | 2025-09-22 |
Holding shares or following this stake? See who's behind Semnur Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Semnur Pharmaceuticals, Inc. and the records around it.
Companies that share a holder
- Scilex Holding Company also filed stake reports on 2 other companies: DATAVAULT AI INC. (Aug 2026), Semnur Pharmaceuticals, Inc. (Jun 2026)
Watch Semnur Pharmaceuticals, Inc.
Get an email when Semnur Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Semnur Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Semnur Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Semnur Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Scilex Holding Company | 500,000 | 188,054,849 | 500,000 | 188,054,849 | SCHEDULE 13D, 2025-09-26 |
| Scilex, Inc. | 0 | 181,804,849 | 0 | 181,804,849 | SCHEDULE 13D, 2025-09-26 |
The latest filing identifies Semnur Pharmaceuticals, Inc. by CUSIP 81686G113 and gives its principal executive office as 960 San Antonio Road, Palo Alto, CA 94303 (SCHEDULE 13D, 2025-09-26).
Source of funds (Item 3)
The Issuer is a majority owned subsidiary of the Reporting Persons. Merger Agreement On September 22, 2025 (the "Closing Date"), the Issuer consummated a business combination (the "Business Combination") pursuant to the terms of that certain Agreement and Plan of Merger, dated as of August 30, 2024, by and among Denali Capital Acquisition Corp. ("SPAC"), Denali Merger Sub, Inc. ("Merger Sub"), and Semnur Pharmaceuticals, Inc. (n/k/a Semnur, Inc.) ("Old Semnur") (as amended by Amendment No. 1 on April 16, 2025 and Amendment No. 2 on July 22, 2025, the "Merger Agreement").Scilex Holding Company, SCHEDULE 13D, 2025-09-26
Purpose of Transaction (Item 4)
Scilex Holding Company
The information set forth in Item 3 is incorporated herein by reference. Subsequent to the consummation of the Business Combination, SHC transferred 554,849 shares of the Issuer's Common Stock and Scilex, Inc. transferred 11,945,151 shares of the Issuer's Common Stock to a third party.Item 4 of the SCHEDULE 13D filed 2025-09-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-26 | Scilex Holding Company | 79.89% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Semnur Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.